Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Revelation Biosciences Inc (REVBW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: REVBW (1-star) is a SELL. SELL since 5 days. Profits (-50.00%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -87.5% | Avg. Invested days 25 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.09 | 52 Weeks Range 0.00 - 0.03 | Updated Date 06/14/2025 |
52 Weeks Range 0.00 - 0.03 | Updated Date 06/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.77 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -54.68% | Return on Equity (TTM) -233.26% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 941937 |
Shares Outstanding - | Shares Floating 941937 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Revelation Biosciences Inc
Company Overview
History and Background
Revelation Biosciences Inc. is a clinical stage biopharmaceutical company focused on the development of immunomodulatory therapies for the prevention and treatment of disease. Founded with a focus on infectious diseases, they are based in San Diego, California. They have shifted their focus and research programs over time, facing significant setbacks and restructuring.
Core Business Areas
- Respiratory Infections: Developing REVTx-99a, a nasal spray for preventing respiratory viral infections. Previously investigated as an adjunct to influenza vaccination.
- Inflammatory Diseases: Exploring potential applications of their platform in inflammatory conditions.
Leadership and Structure
The company is led by an executive team with experience in pharmaceutical development and commercialization. The structure is a typical biotech setup with scientific, clinical, and administrative departments.
Top Products and Market Share
Key Offerings
- REVTx-99a: A nasal spray intended to prevent respiratory viral infections, including influenza. Currently in development, no market share or revenue exists yet. Competitors include companies developing antiviral therapies (e.g., Roche with Tamiflu) and preventative vaccines (e.g., GSK, Moderna, Pfizer).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and regulated, with significant investment required for drug development. Success depends on clinical trial outcomes, regulatory approvals, and commercialization strategies.
Positioning
Revelation Biosciences is a small, clinical-stage company attempting to innovate in the crowded fields of respiratory infections. Their competitive advantage, if any, would be demonstrating superior efficacy or safety compared to existing treatments.
Total Addressable Market (TAM)
The TAM for respiratory infection prevention and treatment is substantial, estimated in the billions of dollars annually. Revelation Biosciences' positioning is speculative; they need to prove efficacy and obtain regulatory approval to capture a meaningful share of the market. The inflammatory disease market is also huge and they are in the early stages to capture the TAM.
Upturn SWOT Analysis
Strengths
- Novel immunomodulatory platform
- Experienced leadership team
- Potential for broad application across multiple diseases
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- No currently marketed products
- History of restructuring and setbacks
Opportunities
- Partnerships with larger pharmaceutical companies
- Successful clinical trial results
- Regulatory approvals
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent challenges
- Inability to secure funding
Competitors and Market Share
Key Competitors
- RHHBY
- MRNA
- PFE
- SNY
Competitive Landscape
Revelation Biosciences is a small player competing against much larger and established pharmaceutical companies with significantly greater resources and existing products.
Growth Trajectory and Initiatives
Historical Growth: Limited historical growth due to being a clinical-stage company. Growth dependent on successful clinical trials.
Future Projections: Future growth is highly uncertain and dependent on the success of REVTx-99a and other pipeline candidates.
Recent Initiatives: Focusing on the development of REVTx-99a for respiratory viral infections.
Summary
Revelation Biosciences is a high-risk, high-reward clinical-stage company. Success hinges on the clinical development and regulatory approval of REVTx-99a. The company faces significant financial and competitive challenges. Investors should carefully consider the risks involved.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Financial News Outlets
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough due diligence and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Revelation Biosciences Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2020-11-16 | Chairman & CEO Mr. James M. Rolke | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.revbiosciences.com |
Full time employees 8 | Website https://www.revbiosciences.com | ||
Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.